Clopidogrel resistance: Pharmacokinetic or pharmacogenetic?

Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2009, Pages 506-512

  Ford, Neville F ^a  

^a Woodfield Clinical Consulting LLC   (United States)

Author keywords

Cardiovascular; Chemistry; Clinical pharmacology; Clinical trials; Disease management; Pharmacogenetics; Pharmacokinetics and drug metabolism

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOPROTEIN P; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; ALLELE; BLOOD SAMPLING; CLINICAL TRIAL; CORONARY STENT; DOSE RESPONSE; DRUG INHIBITION; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER MICROSOME METABOLISM; LOADING DRUG DOSE; NONHUMAN; NOTE; PHARMACOGENETICS; RISK REDUCTION; THERAPY EFFECT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 65449158776     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009332433     Document Type: Note

References (46)

1. The CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of an ischemic event. Lancet. 1996 ; 348: 1329-1339. (Pubitemid 26383772)
2. Yusef S, Zhao F, Mehta SR, et al. The effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevations. N Engl J Med. 2001;345:494-502. 3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction-2002: summary article. Circulation. 2002;106:1893-1900.
3. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance and the effect of pretreatment platelet reactivity. Circulation. 2003 ; 107: 2908-2913. (Pubitemid 36736631)
4. Müller I., Besta F., Schulz C., et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003 ; 89: 783-787. (Pubitemid 36603418)
5. Wang TH, Bhatt DL, Topol EJ Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006 ; 27: 647-654.
6. Agarwal S., Coakely M., Reddy K., et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100«) and modified thromboelastography (mTEG«) with light transmission platelet aggregometry. Anesthesiology. 2006 ; 105: 676-683. (Pubitemid 44477312)
7. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005 ; 45: 1157-1164. (Pubitemid 40523131)
8. Savi P., Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000 ; 84: 891-896.
9. Pereillo JM, Maftouh M., Andrieu A., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002 ; 30: 1288-1295. (Pubitemid 35265838)
10. Dudman NPB, Hicks C., Lynch JF, et al. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb. 1991 ; 11: 663-670.
11. Ding Z., Kim S., Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003 ; 101: 3908-3914. (Pubitemid 36857866)
12. Savi P., Zachayus JL, Delesque-Touchard N., et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. PNAS. 2008 ; 103: 11069-11074. (Pubitemid 44148419)
13. Taubert D., Kastrati A., Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004 ; 92: 311-316. (Pubitemid 39172312)
14. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 ; 81: 735-741. (Pubitemid 46625113)
15. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolism activity to the phenomenon of clopidogrel resistance. Circulation. 2004 ; 109: 166-171. (Pubitemid 38114134)
16. Kurihara A., Hagihara K., Kazui M., et al. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 2005 ; 37 (suppl 2). 99.
17. Clarke TA, Waskell LA The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003 ; 31: 53-59. (Pubitemid 36735258)
18. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003 ; 107: 32-37. (Pubitemid 36070929)
19. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600mg loading dose of clopidogrel in a large unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 ; 111: 2560-2564. (Pubitemid 40740853)
20. Bates ER, Lau WC, Bleske BE Loading, pretreatment and inter-individual variability issues with clopidogrel dosing. Circulation. 2005 ; 111: 2557-2559. (Pubitemid 40740852)
21. P450 table. http://www.medicine.iupui.edu/Flockhart/table. htm.
22. Saw J., Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized placebo-controlled trial. Circulation. 2003 ; 108: 921-924. (Pubitemid 37048218)
23. Suh JWE, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Can Med Assoc J. 2006 ; 174: 1715-1722. (Pubitemid 43893560)
24. Kim KA, Park PW, Park JY Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 2008 ; 64: 589-597.
25. Hulot JS, Bura A., Villani E., et al. Cytochrome P450 2C19 loss of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006 ; 108: 2244-2247. (Pubitemid 44497506)
26. Gilard M., Arnaud B., Le Gal G., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006 ; 4: 2508-2509. (Pubitemid 44575451)
27. Gilard M., Arnaud B., Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 2008 ; 51: 256-260.
28. Schwarz UR, Geiger J., Walter U., et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Thromb Haemost. 1999 ; 82: 1145-1152.
29. Gurbel PA, Lau WC, Tantry US Omeprazole: a possible new candidate influencing the anti-platelet effect of clopidogrel. J Am Coll Cardiol. 2008 ; 51: 261-263.
30. Sibbing D., Morath T., Braun S., et al. Antiplatelet action of clopidogrel is not influenced by proton pump inhibitors in patients with coronary artery disease under clopidogrel maintainence treatment. Eur Heart J. 2008 ; 29 (suppl):abstract 832.
31. Zairis M., Patsourakos N., Makrygiannis S., et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. Eur Heart J. 2008 ; 29 (suppl):abstract 134.
32. Hochholzer W., Trenk D., Bestehorn H., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective stent placement. J Am Coll Cardiol. 2006 ; 48: 1742-1750. (Pubitemid 44648629)
33. Alfonso F., Angiolillo DJ Platelet function assessment to predict outcomes after coronary interventions: hype or hope ? J Am Coll Cardiol. 2006 ; 48: 1751-1754.
34. O'Donnell CJ, Larson MG, Feng DL, et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation. 2001 ; 103: 3051-3056. (Pubitemid 32587850)
35. Taubert D., von Beckerath N., Grimberg G., et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 ; 80: 486-501.
36. Von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization and antiplatelet effects of 30-, 600-, and 900m-mg loading doses of clopidogrel; results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between three high oral doses for immediate clopidogrel effect) trial. Circulation. 2005 ; 112: 2946-2950. (Pubitemid 41612296)
37. Giusti B., Gori AM, Marcucci R., et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual anti-platelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007 ; 17: 1057-1064.
38. Frere C., Cuissert T., Morange PE, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndromes. Am J Cardiol. 2008 ; 101: 1088-1093.
39. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12 receptor mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008 ; 29: 21-30.
40. Trenk D., Hochholzer W., Fromm MF, et al. Cytochrome P-450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008 ; 51: 1925-1934.
41. Cairns JA, Eikelboom J. Clopidogrel resistance: more grist for the mill. J Am Coll Cardiol. 2008 ; 51: 1935-1937.
42. Wiviott SD, Braunwald E., McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357: 2001-2015. (Pubitemid 350106708)
43. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 ; 360: 354-362.
44. Cavallari U., Trabetti E., Malerba G., et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genetics. 2007 ; 8: 59. (Pubitemid 350041725)
45. Cuisset T., Frere C., Quilici J., et al. Role of the T744C polymorphism of the P2Y12 gene on platelet responsiveness to a 600-mg loading dose of clodigrel in 597 patients with non-ST segment elevation acute coronary syndrome. Thromb Res. 2007 ; 120: 893-899. (Pubitemid 47432706)
46. Fontana P., Dupont A., Grandrille S., et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003 ; 108: 989-995. (Pubitemid 37048230)